25-04-2013 дата публикации
Номер: US20130102767A1
Принадлежит:
Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants. 1. An isolated nucleic acid comprising a polypeptide coding sequence having at least 99 percent identity to SEQ ID NO:2. This application is a continuation-in-part of U.S. patent application Ser. No. 13/157,066, filed Jun. 9, 2011, which is a continuation-in-part of U.S. patent application Ser. No. 12/639,295, filed Dec. 16, 2009 (now U.S. Pat. No. 7,989,609), which is a continuation-in-part of U.S. patent application Ser. No. 12/040,538, filed Feb. 29, 2008 (now U.S. Pat. No. 7,659,386), which is a continuation-in-part of U.S. patent application Ser. No. 11/368,321, filed Mar. 3, 2006 (now U.S. Pat. No. 7,365,183), which is a continuation-in-part of U.S. patent application Ser. No. 11/006,231, filed Dec. 6, 2004, which is a continuation of U.S. patent application Ser. No. 10/645,822, filed Aug. 22, 2003, which is a continuation-in-part of the following U.S. Patent Applications: (a) U.S. patent application Ser. No. 10/336,798, filed Jan. 6, 2003, which is a continuation of U.S. patent application Ser. No. 10/136,365, filed May 2, 2002, which claims priority to U.S. patent application Ser. No. 09/731,809, filed Dec. 8, 2000, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/169,691, filed Dec. 8, 1999, (b) U.S. patent application Ser. No. 09/513,996, filed Feb. 25, 2000, which is a continuation-in-part of and claims priority to U.S. Provisional Patent Application No. 60/169,691, filed Dec. 8, 1999, and (c) U.S. patent application Ser. No. 10/461,476, filed Jun. 16, 2003, which is a continuation of U.S. patent application Ser. No. 10/191,406, filed Jul. 10, 2002, which is a continuation of U.S. patent application Ser. No. 09/940,255, filed Aug. 24, 2001. The entire contents of these related applications are incorporated by reference in their entirety. This application claims priority to ...
Подробнее
